Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1912 1
1923 1
1930 1
1946 1
1948 4
1949 1
1951 1
1963 1
1964 2
1967 1
1968 1
1969 1
1970 9
1971 4
1972 5
1973 9
1974 5
1975 13
1976 11
1977 10
1978 9
1979 3
1980 11
1981 10
1982 12
1983 8
1984 10
1985 20
1986 22
1987 8
1988 13
1989 10
1990 11
1991 7
1992 7
1993 15
1994 12
1995 15
1996 8
1997 16
1998 17
1999 12
2000 9
2001 16
2002 22
2003 14
2004 27
2005 32
2006 42
2007 31
2008 21
2009 25
2010 21
2011 45
2012 35
2013 43
2014 54
2015 51
2016 34
2017 29
2018 25
2019 13
2020 25
2021 24
2022 28
2023 21
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

937 results

Results by year

Filters applied: . Clear all
Page 1
The three Es of cancer immunoediting.
Dunn GP, Old LJ, Schreiber RD. Dunn GP, et al. Annu Rev Immunol. 2004;22:329-60. doi: 10.1146/annurev.immunol.22.012703.104803. Annu Rev Immunol. 2004. PMID: 15032581 Free article. Review.
A review of glioblastoma immunotherapy.
Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. Medikonda R, et al. Among authors: dunn g. J Neurooncol. 2021 Jan;151(1):41-53. doi: 10.1007/s11060-020-03448-1. Epub 2020 Apr 6. J Neurooncol. 2021. PMID: 32253714 Review.
Comprehensive Analysis of Hypermutation in Human Cancer.
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Campbell BB, et al. Among authors: dunn gp. Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19. Cell. 2017. PMID: 29056344 Free PMC article.
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E, Chang SM, Nabors LB, Ahluwalia MS, Stupp R, Mehta MP, Reardon DA, Grossman SA, Sulman EP, Sampson JH, Khagi S, Weller M, Cloughesy TF, Wen PY, Khasraw M. Bagley SJ, et al. Among authors: dunn gp. Clin Cancer Res. 2022 Feb 15;28(4):594-602. doi: 10.1158/1078-0432.CCR-21-2750. Clin Cancer Res. 2022. PMID: 34561269 Free PMC article. Review.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira G, Egloff AM, Afeyan AB, Wolff JO, Zeng Z, Chernock RD, Zhou L, Messier C, Lizotte P, Pfaff KL, Stromhaug K, Penter L, Haddad RI, Hanna GJ, Schoenfeld JD, Goguen LA, Annino DJ, Jo V, Oppelt P, Pipkorn P, Jackson R, Puram SV, Paniello RC, Rich JT, Webb J, Zevallos JP, Mansour M, Fu J, Dunn GP, Rodig SJ, Ley J, Morris LGT, Dunn L, Paweletz CP, Kallogjeri D, Piccirillo JF, Adkins DR, Wu CJ, Uppaluri R. Oliveira G, et al. Among authors: dunn gp. Sci Immunol. 2023 Sep 8;8(87):eadf4968. doi: 10.1126/sciimmunol.adf4968. Epub 2023 Sep 8. Sci Immunol. 2023. PMID: 37683037 Free PMC article.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Among authors: dunn gp. Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665297 Free PMC article. Clinical Trial.
Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma.
Mahlokozera T, Patel B, Chen H, Desouza P, Qu X, Mao DD, Hafez D, Yang W, Taiwo R, Paturu M, Salehi A, Gujar AD, Dunn GP, Mosammaparast N, Petti AA, Yano H, Kim AH. Mahlokozera T, et al. Among authors: dunn gp. Nat Commun. 2021 Nov 3;12(1):6321. doi: 10.1038/s41467-021-26653-6. Nat Commun. 2021. PMID: 34732716 Free PMC article.
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.
Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P, Miska J, Yeeravalli R, Habashy K, Saganty R, Kang SJ, Fares J, Liu C, Dunn G, Bartom E, Schipma MJ, Hsu PD, Alghamri MS, Lesniak MS, Heimberger AB, Rabadan R, Lee-Chang C, Sonabend AM. Dmello C, et al. Among authors: dunn g. Nat Commun. 2023 Mar 22;14(1):1566. doi: 10.1038/s41467-023-36878-2. Nat Commun. 2023. PMID: 36949040 Free PMC article.
937 results